ELVN earnings: next report 2026-08-12, real EPS beat/miss history, analyst consensus Buy, P/E -32.23. Updated 2026-07-23.
Enliven Therapeutics (ELVN) Research Hub
Enliven Therapeutics (ELVN) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 54.32 USD (-5.45%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -32.23, market cap 3.83B. This hub links to the full technical, earnings and options research available for ELVN.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 54.32 USD (-5.45%) |
| 52-week range | 41.42 USD – 62 USD |
| Trend regime | Range |
| 14-day RSI | 30.8 (Bearish) |
| Trailing P/E | -32.23 |
| Market cap | 3.83B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-12 |
Available research for ELVN
Covered Call on ELVN: how it works, illustrative setup around the real 54.32 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on ELVN: how it works, illustrative setup around the real 54.32 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on ELVN: how it works, illustrative setup around the real 54.32 USD price, max profit/loss, breakeven and when to use it. Educational.
ELVN technical analysis: range, last 54.32 USD, RSI 30.8, 52w range 41.42 USD–62 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is ELVN in?
Enliven Therapeutics (ELVN) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is ELVN in an uptrend or downtrend?
As of 2026-09-11, ELVN is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is ELVN's trailing P/E ratio?
ELVN's trailing P/E is -32.23, with a market cap of 3.83B. See the earnings research page for full valuation detail.
When does ELVN next report earnings?
ELVN is next scheduled to report earnings on 2026-08-12, with a consensus EPS estimate of -0.38 USD.